1-12 of 12
Beth Wilmot, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort

Daniel Bottomly, Nicola Long, Fei Yang, MD, Tiffany Lee, MD, Uma Borate, MD, Beth Wilmot, PhD, Adam S DuVall, MD, Andrea Monteblanco, BS, Karina Thiel-Klare, Gabby Dewson, BA, Richard D. Press, MD PhD, Cristina E. Tognon, Brian J. Druker, Jeffrey W. Tyner, Shannon K. McWeeney, PhD, Anupriya Agarwal, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1407.
https://doi.org/10.1182/blood-2019-132224
Published: 2019
Journal Articles

Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment

Haijiao Zhang, Beth Wilmot, PhD, Daniel Bottomly, Stephen E Kurtz, PhD, Christopher A. Eide, Alisa Damnernsawad, Kyle Romine, Shyam Patel, Brian J. Druker, MD, Schannon K Mcweeney, Ravi Majeti, MD PhD, Jeffrey W. Tyner, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 175.
https://doi.org/10.1182/blood-2018-175
Published: 2018
Journal Articles

Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia

Bill H. Chang, MD PhD, Jessica Leonard, MD, Joelle Wolf, Michelle Degnin, BS, Kyle Lenz, MD, Beth Wilmot, PhD, Charles G. Mullighan, MBBS, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4026.
https://doi.org/10.1182/blood-2018-99-115706
Published: 2018
Journal Articles

Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, Samantha L Savage, Anna M. Reister Schultz, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Motomi Mori, PhD, Elie Traer, MD PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2068.
https://doi.org/10.1182/blood.V130.Suppl_1.2068.2068
Published: 2017
Journal Articles

Therapeutically Targetable Activating c-ABL1 Mutations in Philadelphia Chromosome-Negative Leukemias

Samantha L Savage, Julia E. Maxson, PhD, Christopher A. Eide, Chelsea Jenkins, B.S., Melissa L Abel, Anna M. Reister Schultz, Daniel Bottomly, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Cristina E. Tognon, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3930.
https://doi.org/10.1182/blood.V130.Suppl_1.3930.3930
Published: 2017
Journal Articles

CG '806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition As a Single Agent and in Combination with a BET Bromodomain Inhibitor or a Bcl2 Inhibitor on Primary AML and CLL Patient Samples

Stephen E Kurtz, PhD, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Andrea Local, PhD, Hongying Zhang, MD, Stephen Howell, MD, William Rice, PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4626.
https://doi.org/10.1182/blood.V130.Suppl_1.4626.4626
Published: 2017
Journal Articles

Coexisting Oncogenic Signaling Pathway Mutations in Cnl/Acml/CMML/MPN-U

Haijiao Zhang, Daniel Bottomly, Libbey K. White, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Jeffrey W. Tyner, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4213.
https://doi.org/10.1182/blood.V130.Suppl_1.4213.4213
Published: 2017
Journal Articles

Differential Ex Vivo Sensitivity Patterns to Small-Molecule Inhibitors and Combination Therapies Among Acute Myeloid Leukemia Patients Harboring Both FLT3 and NPM1 Mutations

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, Andrew Park, Angela Rofelty, Beth Wilmot, PhD, Daniel Bottomly, Shannon K. McWeeney, PhD, Cristina E. Tognon, PhD, Motomi Mori, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1422.
https://doi.org/10.1182/blood.V130.Suppl_1.1422.1422
Published: 2017
Journal Articles

Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level

Stephen E. Kurtz, PhD, Daniel Bottomly, MS, Beth Wilmot, PhD, Shannon K. McWeeney, PhD, William Rice, PhD, Stephen B Howell, MD, Avanish Vellanki, Brian J. Druker, MD, Jeffrey W. Tyner, PhD
Journal: Blood
Blood (2015) 126 (23): 1358.
https://doi.org/10.1182/blood.V126.23.1358.1358
Published: 2015
Journal Articles

Activating Mutations of Insulin Receptor Substrate 2 (IRS2) in Patients with Tyrosine Kinase Inhibitor-Refractory Chronic Myeloid Leukemia

Samantha L Savage, Christopher A. Eide, Kyle F Concannon, Daniel Bottomly, MS, Beth Wilmot, PhD, Shannon K. McWeeney, PhD, Julia Elizabeth Maxson, PhD, Jeffrey W. Tyner, PhD, Cristina E. Tognon, PhD, Brian J. Druker, MD
Journal: Blood
Blood (2015) 126 (23): 2461.
https://doi.org/10.1182/blood.V126.23.2461.2461
Published: 2015
Journal Articles

Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib

Haijiao Zhang, MD, Kevin Matthew Watanabe-Smith, BS, Daniel Bottomly, MS, Beth Wilmot, PhD, Shannon K. McWeeney, PhD, Hagop M. Kantarjian, MD, Judy Ho, Jeremy Davis, Blake Pond, MS, Gautam Borthakur, MD, Abhijit Ramachandran, MS, Jorge E. Cortes, Robert Collins, MD, Jeffrey W. Tyner, PhD
Journal: Blood
Blood (2015) 126 (23): 2468.
https://doi.org/10.1182/blood.V126.23.2468.2468
Published: 2015
Journal Articles

A Truncation Mutant of CSF3R, Identified As a Novel Driver in De Novo Myeloid Leukemia, Signals Through TNK2, and Is Responsive to Dasatinib.

Julia E Maxson, PhD, Jason Gotlib, Angela G. Fleischman, MD, PhD, Christopher A. Eide, Daniel Bottomly, MS, Beth Wilmot, PhD, MS, Shannon McWeeney, PhD, Cristina Tognon, PhD, Marc M Loriaux, MD, PhD, Brian J. Druker, Jeffrey W Tyner, PhD
Journal: Blood
Blood (2012) 120 (21): 2412.
https://doi.org/10.1182/blood.V120.21.2412.2412
Published: 2012